Literature DB >> 30194036

Adenocarcinoma of the Lung in Childhood and Adolescence: A Systematic Review.

Ben W R Balzer1, Christine Loo2, Craig R Lewis3, Toby N Trahair4, Antoinette C Anazodo5.   

Abstract

Primary lung cancer is extremely rare in children. It often presents with metastatic disease and carries a poor prognosis. Adenocarcinoma is the most common type of bronchogenic carcinoma in children and adults. Our aim was to systematically review the presenting features, approach to diagnosis and management, as well as the outcomes of primary pediatric adenocarcinoma of the lung. This systematic review was prospectively registered with PROSPERO. The following databases were searched: Medline, Embase, Web of Science, and Scopus for English language cases of primary pediatric adenocarcinoma of the lung. Forty-eight studies were included, comprising 62 patients with adenocarcinoma and 21 cases of adenocarcinoma in situ. Presenting features were nonspecific, with cough and dyspnea the main symptoms at diagnosis. The majority of patients with adenocarcinoma had metastatic disease at diagnosis. Surgery was the most common form of management. More than half the patients with adenocarcinoma had died at final follow-up, whereas 5 of 21 with adenocarcinoma in situ died. Medical management did not improve outcomes, except for two ALK receptor tyrosine kinase (ALK)-rearranged adenocarcinomas that responded to ALK inhibitor therapy alone. Primary pediatric adenocarcinoma of the lung is a rare entity which often presents with metastatic disease and portends a poor prognosis. Surgery is associated with disease-free status, although new agents such as ALK-inhibitors are able to prolong life without surgical management.
Copyright © 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Bronchioloalveolar carcinoma; Lung neoplasms; Pediatrics

Mesh:

Year:  2018        PMID: 30194036     DOI: 10.1016/j.jtho.2018.08.2020

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  11 in total

1.  A model of twenty-three metabolic-related genes predicting overall survival for lung adenocarcinoma.

Authors:  Zhenyu Zhao; Boxue He; Qidong Cai; Pengfei Zhang; Xiong Peng; Yuqian Zhang; Hui Xie; Xiang Wang
Journal:  PeerJ       Date:  2020-09-24       Impact factor: 2.984

2.  LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma.

Authors:  Junbin Wang; Jin Gao; Qinnan Chen; Weiyan Zou; Fen Yang; Chenchen Wei; Zhaoxia Wang
Journal:  Onco Targets Ther       Date:  2020-09-22       Impact factor: 4.147

3.  Down-regulated NEDD4L facilitates tumor progression through activating Notch signaling in lung adenocarcinoma.

Authors:  Liping Lin; Xuan Wu; Yuanxue Jiang; Caijiu Deng; Xi Luo; Jianjun Han; Jiazhu Hu; Xiaolong Cao
Journal:  PeerJ       Date:  2022-05-24       Impact factor: 3.061

4.  Epidemiology and outcomes of primary pediatric lung malignancies: Updates from the SEER database.

Authors:  Nathan J Smith; Devashis Mukherjee; Yu Wang; Ruta Brazauskas; Ariel A Nelson; Chandler S Cortina
Journal:  Am J Surg       Date:  2021-02-01       Impact factor: 3.125

Review 5.  Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance.

Authors:  Swastika Maity; K Sreedhara Ranganath Pai; Yogendra Nayak
Journal:  Pharmacol Rep       Date:  2020-07-14       Impact factor: 3.024

6.  Ground glass opacity featured lung adenocarcinoma in teenagers.

Authors:  Haoxuan Wu; Yang Zhang; Hong Hu; Yuan Li; Xuxia Shen; Quan Liu; Shengping Wang; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-07       Impact factor: 4.553

7.  Expression Profile and Prognostic Values of CDH Family Members in Lung Adenocarcinoma.

Authors:  Feng Li; Bin Wan; Xiao-Qing Li
Journal:  Dis Markers       Date:  2022-02-11       Impact factor: 3.434

8.  LncRNA LINC00520 aggravates cell proliferation and migration in lung adenocarcinoma via a positive feedback loop.

Authors:  Wen Huang; Xinxing Wang; Fubing Wu; Fanggui Xu
Journal:  BMC Pulm Med       Date:  2021-09-08       Impact factor: 3.317

9.  Transcriptomic data exploration of consensus genes and molecular mechanisms between chronic obstructive pulmonary disease and lung adenocarcinoma.

Authors:  Siyu Zhang; Kun Pang; Xinyu Feng; Yulan Zeng
Journal:  Sci Rep       Date:  2022-08-02       Impact factor: 4.996

10.  Systematic identification of clinically relevant miRNAs for potential miRNA-based therapy in lung adenocarcinoma.

Authors:  Shu-Hsuan Liu; Kai-Wen Hsu; Yo-Liang Lai; Yu-Feng Lin; Fang-Hsin Chen; Pei-Hwa Peng; Li-Jie Lin; Heng-Hsiung Wu; Chia-Yang Li; Shu-Chi Wang; Min-Zu Wu; Yuh-Pyng Sher; Wei-Chung Cheng
Journal:  Mol Ther Nucleic Acids       Date:  2021-05-01       Impact factor: 8.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.